Neuronal degeneration and mitochondrial dysfunction

Journal of Clinical Investigation

Volumn 111, Issue 3, 2003, Pages 303-312

  Schon, Eric A ^a   Manfredi, Giovanni ^b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CELL DEATH; CLINICAL FEATURE; DEGENERATIVE DISEASE; DISEASE COURSE; FRIEDREICH ATAXIA; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HUNTINGTON CHOREA; INHERITANCE; LEIGH DISEASE; MITOCHONDRION; NERVE CELL DEGENERATION; NEUROPATHOLOGY; PARKINSON DISEASE; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; REVIEW; SPASTIC PARAPLEGIA; WILSON DISEASE;

ANIMALS; CELL DEATH; DNA, MITOCHONDRIAL; ELECTRON TRANSPORT; FRIEDREICH ATAXIA; HUMANS; MITOCHONDRIA; MODELS, BIOLOGICAL; MODELS, GENETIC; MUTATION; NEURODEGENERATIVE DISEASES; NEURONS;

EID: 0037314215     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200317741     Document Type: Review

References (64)

1. Anderson, S., et al. 1981. Sequence and organization of the human mitochondrial genome. Nature. 290:457-465.
2. Schon E.A., Bonilla, E., and DiMauro, S. 1997. Mitochondrial DNA mutations and pathogenesis. J. Bioenerg. Biomembr. 29:131-149.
3. Cavadini, P., O'Neill, H.A., Benada, O., and Isaya, G. 2002. Assembly and iron-binding properties of human frataxin, the protein deficient in Friedreich ataxia. Hum. Mol. Genet. 11:217-227.
4. Gakh, O., et al. 2002. Physical evidence that yeast frataxin is an iron storage protein. Biochemistry. 41:6798-6804.
5. Puccio, H. 2001. Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits. Nat. Genet. 27:181-186.
6. Rustin, P., et al. 1999. Effect of idebenone on cardiomyopathy in Friedreich's ataxia: a preliminary study. Lancet. 354:477-479.
7. Schulz, J.B., et al. 2000. Oxidative stress in patients with Friedreich ataxia. Neurology. 55:1719-1721.
8. Casari, G., et al. 1998. Spastic paraplegia and OXPHOS impairment caused by mutations in paraplegin, a nuclear-encoded mitochondrial metalloprotease. Cell. 93:973-983.
9. Hansen, JJ., et al. 2002. Hereditary spastic paraplegia SPG13 is associated with a mutation in the gene encoding the mitochondrial chaperonin Hsp60. Am. J. Hum. Genet. 70:1328-1332.
10. Jin, H., et al. 1996. A novel X-linked gene, DDP, shows mutations in families with deafness (DFN-1), dystonia, mental deficiency and blindness. Nat. Genet. 14:177-180.
11. Roesch, K., Curran, S.P., Tranebjaerg, L., and Koehler, C.M. 2002. Human deafness dystonia syndrome is caused by a defect in assembly of the DDP1/TIMM8a-TIMM13 complex. Hum. Mol. Genet. 11:477-486.
12. Lutsenko, S., and Cooper, MJ. 1998. Localization of the Wilson's disease protein product to mitochondria. Proc. Natl. Acad. Sci. USA. 95:6004-6009.
13. Orth, M., and Schapira, A.H. 2001. Mitochondria and degenerative disorders. Am. J. Med. Genet. 106:27-36.
14. Smith, M.A., et al. 2002. Amyloid-beta, tau alterations and mitochondrial dysfunction in Alzheimer disease: the chickens or the eggs? Neurochem. Int. 40:527-531.
15. Busciglio, J., et al. 2002. Altered metabolism of the amyloid β precursor protein is associated with mitochondrial dysfunction in Down's syndrome. Neuron. 33:677-688.
16. Casley, C.S., et al. 2002. Beta-amyloid inhibits integrated mitochondrial respiration and key enzyme activities. J. Neurochem. 80:91-100.
17. Mutisya, E.M., Bowling, A.C., and Beal, M.F. 1994. Cortical cytochrome oxidase activity is reduced in Alzheimer's disease. J. Neurochem. 63:2179-2184.
18. Bonilla, E., et al. 1999. Mitochondrial involvement in Alzheimer's disease. Biochim. Biophys. Acta. 1410:171-182.
19. Ojaimi, J., et al. 1999. Irregular distribution of Cytochrome c oxidase protein subunits in aging and Alzheimer's disease. Ann. Neurol. 46:656-660.
20. Kong, J., and Xu, Z. 1998. Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. J. Neurosci. 18:3241-3250.
21. Browne, S.E., et al. 1998. Metabolic dysfunction in familial, but not sporadic, amyotrophic lateral sclerosis. J. Neurochem. 71:281-287.
22. Mattiazzi, M., et al. 2002. Mutated human SOD1 causes dysfunction of oxidative phosphorylation in mitochondria of transgenic mice. J. Biol. Chem. 27:29626-29633.
23. Klivenyi, P., et al. 1999. Neuroprotective effects ofcreatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat. Med. 5:347-350.
24. Sasaki, S., and Iwara, M. 1996. Impairment of fast axonal transport in the proximal axons of anterior horn neurons in amyotrophic lateral sclerosis. Neurology. 47:535-540.
25. Borthwick, G.M., et al. 1999. Mirochondrial enzyme activity in amyotrophic lateral sclerosis: implications for the role of mitochondria in neuronal cell death. Ann. Neurol. 46:787-790.
26. Wiedemann, F.R., et al. 2002. Mitochondrial DNA and respiratory chain function in spinal cords of ALS patients. J. Neurochem. 80:616-625.
27. Okado-Matsumoto, A., and Fridovich, I. 2002. Amyotrophic lateral sclerosis: a proposed mechanism. Proc. Natl. Acad. Sci. USA. 99:9010-9014.
28. Kunst, C.B., Mezey, E., Brownstein, MJ., and Patterson, D. 1997. Mutations in SOD1 associated with amyotrophic lateral sclerosis cause novel protein interactions. Nat. Genet. 15:91-94.
29. Menzies, F.M., Ince, P.G., and Shaw, P.J. 2002. Mitochondrial involvement in amyotrophic lateral sclerosis. Neurochem. Int. 40:543-551.
30. Zhu, S., et al. 2002. Minocycline inhibits cytochrome c release and delays progression ofamyotrophic lateral sclerosis in mice. Nature. 417:74-78.
31. Subramaniam, J.R., et al. 2002. Mutant SOD1 causes motor neuron disease independent of copper chaperone-mediated copper loading. Nat. Neurosci. 5:301-307.
32. 1H NMR spectroscopy. Neurology. 43:2689-2695.
33. Koroshetz, W.J., Jenkins, B.G., Rosen, B.R., and Beal, M.F. 1997. Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. Ann. Neurol. 41:160-165.
34. Beal, M.F., et al. 1993. Age-dependent striatal excitotoxic lesions produced by the endogenous mitochondrial inhibitor malonate. J. Neurochem. 61:1147-1150.
35. Panov, A.V., et al. 2002. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat. Neurosci. 5:731-736.
36. Arnould, T., et al. 2002. CREB activation induced by mitochondrial dysfunction is a new signaling pathway that impairs cell poliferation. EMBO J 21:53-63.
37. Yu, Z.X., Li, S.H., Nguyen, H.P., and Li, X.J. 2002. Huntingtin inclusions do not deplete polyglutamine-containing transcription factors in HD mice. Hum. Mol. Genet. 11:905-914.
38. Gervais, F.G., et al. 2002. Recruitment and activation of caspase-8 by the Huntingtin-interacting protein Hip-1 and a novel partner Hippi. Nat. Cell Biol. 4:95-105.
39. Dexter, D.T., et al. 1994. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann. Neurol. 35:38-44.
40. Choi, P., et al. 2001. Co-association of parkin and alpha-synuclein. New roreport. 12:2839-2843.
41. Elkon, H., et al. 2002. Mutant and wild-type alpha-synuclein interact with mitochondrial cytochrome c oxidase. J. Mol. Neurosci. 18:229-238.
42. Lee, H.J., Choi, C., and Lee, S.J. 2002. Membrane-bound alpha-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form. J. Biol. Chem. 277:671-678.
43. Lee, H.J., et al. 2002. Formation and removal of alpha-synuclein aggregates in cells exposed to mitochondrial inhibitors. J. Biol. Chem. 277:5411-5417.
44. Finsterer, J. 2002. Parkinson syndrome as a manifestation of mitochondriopathy. Acta Neurol. Scand. 105:384-389.
45. Albers, D.S., et al. 2000. Frontal lobe dysfunction in progressive supranuclear palsy: evidence for oxidative stress and mitochondrial impairment. J. Neurochem. 74:878-881.
46. Park, L.C., et al. 2001. Mitochondrial impairment in the cerebellum of the patients with progressive supranuclear palsy. J. Neurosci. Res. 66:1028-1034.
47. Kroemer, G., and Reed, J.C. 2000. Mitochondrial control of cell death. Nat. Med. 6:513-519.
48. Mitsui, T., et al. 1996. Oxidative damage to skeletal muscle DNA from patients with mitochondrial encephalomyopathies. J. Neurol. Sci. 139:111-116.
49. Filosto, M., et al. 2002. Antioxidant agents have a different expression pattern in muscle fibers of patients with mitochondrial diseases. ActaNeuropathol. (Berl.) 103:215-220.
50. Umaki, Y., et al. 2002. Apoptosis-related changes in skeletal muscles of patients with mitochondrial diseases. Acta Neuropathol. (Berl) 103:163-170.
51. Li, Y., et al. 1995. Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase. Nat. Genet. 11:376-381.
52. Murakami, K., et al. 1998. Mitochondrial susceptibility to oxidative stress exacerbates cerebral infarction that follows permanent focal cerebral ischemia in mutant mice with manganese superoxide dismutase deficiency. J. Neurosci. 18:205-213.
53. Melov, S., et al. 2001. Lifespan extension and rescue of spongiform encephalopathy in superoxide dismutase 2 nullizygous mice treated with superoxide dismutase-catalase mimetics. J. Neurosci. 21:8348-8353.
54. Mirabella, M., et al. 2000. Apoptosis in mitochondrial encephalomyopathies with mitochondrial DNA mutations: a potential pathogenic mechanism. Brain. 123:93-104.
55. Di Giovanni, S., et al. 2001. Apoptosis and ROS detoxification enzymes correlate with cytochrome c oxidase deficiency in mitochondrial encephalomyopathies. Mol. Cell. Neurosci. 17:696-705.
56. Sciacco, M., et al. 2001. Lack ofapoptosis in mitochondrial encephalomyopathies. Neurology. 56:1070-1074.
57. Ikezoe, K., et al. 2002. Apoptosis is suspended in muscle of mitochondrial encephalomyopathies. Acta Neuropathol. (Berl.) 103:531-540.
58. Zou, H., et al. 1997. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation ofcaspase-3. Cell. 90:405-413.
59. Burgess, D.H.,et al. 1999. Human skeletal muscle cytosols are refractory to cytochrome c-dependent activation of type-II caspases and lack APAF-1. Cell Death Differ. 6:256-261.
60. Yoshida, H., et al. 1998. Apaf1 is required for mitochondrial pathways of apoptosis and brain development. Cell. 94:739-750.
61. Miyazaki, K., et al. 2001. Caspase-independent cell death and mitochondrial disruptions observed in the Apaf1-deficient cells. J Biochem. (Tokyo). 129:963-969.
62. Koseki, T., Inohara, N., Chen, S., and Nunez, G. 1998. ARC, an inhibitor of apoptosis expressed in skeletal muscle and heart that interacts selectively with caspases. Proc. Natl. Acad. Sci. USA. 95:5156-5160.
63. Neuss, M., et al. 2001. The apoptotic regulatory protein ARC (apoptosis repressor with caspase recruitment domain) prevents oxidant stressmediated cell death by preserving mitochondrial function. J. Biol. Chem. 276:33915-33922.
64. Servidei, S. 2002. Mitochondrial encephalomyopathies: gene mutation. Neuromuscul. Disord. 12:334-339.